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Abstract
Azathioprine (AZA), methotrexate, or rituximab is used for the maintenance therapy of antineutrophil cytoplasmic antibody-
associated vasculitis (AAV). Although the efficacy of tacrolimus (TAC) in various autoimmune diseases has been demonstrated, there
have been few reports on the efficacy of TAC in AAV. We investigated the efficacy of TAC as maintenance therapy for AAV and
compared its efficacy with that of AZA.
We retrospectively analyzed the medical records of 81 patients with AAV who received cyclophosphamide as induction therapy
and AZA or TAC as maintenance therapy. All-cause death, relapse, and progression to end-stage renal disease (ESRD) were
analyzed.
Among 81 patients with AAV, 69 patients received AZA alone, 6 patients received TAC alone, and 6 patients received TAC after
AZA for maintenance therapy. Overall, 11 patients (13.6%) died, 30 patients (37.0%) experienced relapse, and 16 patients (19.8%)
progressed to ESRD during a median of 33.8months. No significant differences were observed in cumulative patients’, relapse-free,
and ESRD-free survival rates between patients administered AZA alone and TAC alone. There were no significant differences in the
cumulative patients’ and relapse-free survival rate between patients who received AZA alone and TAC after AZA. However, the
cumulative ESRD-free survival rate was lower in patients who received TAC after AZA than in those who received AZA alone
(P= .027).
Patients who received TAC as maintenance therapy showed a higher incidence of ESRD than those who received AZA; however,
this might be attributed to the lack of efficacy of AZA rather than the low ESRD prevention effect of TAC.
Abbreviations: AAV = antineutrophil cytoplasmic antibody-associated vasculitis, ANCA = antineutrophil cytoplasmic antibody,
AZA = azathioprine, BVAS = Birmingham vasculitis activity score, C = cytoplasmic, CYC = cyclophosphamide, ESRD = end-stage
renal disease, FFS = five-factor score, GPA = granulomatosis with polyangiitis, MMF = mycophenolate mofetil, MPO =
myeloperoxidase, MTX = methotrexate, P = perinuclear, PR3 = proteinase 3, RTX = rituximab, TAC = tacrolimus.
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Antineutrophil cytoplasmic antibody (ANCA)-associated vascu-
litis (AAV) is a small vessel vasculitis characterized by necrotizing
vasculitis, presenting no or few immune complex deposits in
organ tissues.[1] AAV is divided into 3 subtypes based on clinical,
laboratory, radiological, and histological features—microscopic
polyangiitis, granulomatosis with polyangiitis (GPA), and
eosinophilic GPA.[2]
The treatment of AAV is categorized into induction therapy
and maintenance therapy, with induction therapy particularly
aimed at remission induction.[3] For induction therapeutic
regimens, in the case of organ or life-threatening diseases, either
cyclophosphamide (CYC) or rituximab (RTX), along with
glucocorticoids, is recommended.[4–7] Particularly, for serious
diffuse alveolar hemorrhage with rapidly progressive renal
failure, plasma exchange should be considered.[4,8] In cases of
non-organ or life-threatening disease, eithermethotrexate (MTX)
or mycophenolate mofetil (MMF), along with glucocorticoids, is
recommended.[4,9] For maintenance therapeutic regimens after
remission, azathioprine (AZA), MTX, or RTX, along with
glucocorticoids, is recommended.[4,10] Moreover, maintenance
therapy is recommended for at least 2years.[4]
Tacrolimus (TAC) is a macrolide calcineurin inhibitor and has
been widely used for treating autoimmune diseases and
preventing graft failure after organ transplantation.[11,12]
In autoimmune diseases, pro-inflammatory cytokines, includ-
ing tumor necrosis factor-a and interleukin-1, can enhance
intracellular ionized calcium (Ca++) concentration; thus, activity
of calcineurin/nuclear factor of activated T cells increases.
Consequently, alterations in autoreactive immune cells may
occur; for instance, T cell activation, proliferation, and
differentiation from naive T cells to TH1 and TH17 cells may
be noticeably augmented.[13] TAC inhibits calcineurin phospha-
tase and downregulates calcium-dependent pathways.
Considering changes in pro-inflammatory cytokines and the
subsequent activation of autoreactive immune cells play an
important role in the pathogenesis of AAV,[14–16] it could be
postulated that TAC may be a beneficial therapeutic alternative
for treating AAV, possibly as effective as AZA or MTX as
maintenance therapy. Nevertheless, only a few cases on the
efficacy of TAC in treating AAV have been reported.[17,18]
Furthermore, there have been no previous reports on the
therapeutic potential of TAC in a considerable number of
patients with AAV. Hence, in this study, we investigated the
efficacy of TAC as maintenance therapy for AAV treatment and
compared its efficacy with that of AZA.2. Methods
2.1. Patients
The medical records of 223 patients with AAV were
retrospectively reviewed. All patients were initially diagnosed
or reclassified as AAV at the Division of Rheumatology,
Department of Internal Medicine, Yonsei University College of
Medicine, Severance Hospital, from October 2000 to March
2020. Furthermore, all patients met both the 2007 European
Medicines Agency algorithm for polyarteritis nodosa and AAV
and the 2012 revised International Chapel Hill Consensus
Conference Nomenclature of Vasculitides.[1,2] The inclusion
criteria were as follows: patients who received CYC as
induction therapy and patients who received AZA or TAC as2
maintenance therapy. The exclusion criteria were as follows:
patients who received other immunosuppressive drugs, such as
MMF or MTX, for maintenance therapy, patients who had a
follow-up period of less than 3months, and patients presenting
serious concomitant medical conditions, such as malignancy,
serious infection, and other systemic vasculitides other than
AAV.2.2. Study population
Among 223 patients with AAV, 106 patients who did not receive
CYC as induction therapy were excluded. Furthermore, among
117 patients with AAV who received CYC as induction therapy,
7 patients who received MMF alone or MMF after AZA, 22
patients who received MTX alone or MTX after AZA, and 7
patients who received no immunosuppressive agents as mainte-
nance therapy were excluded. Finally, 81 patients with AAVwho
received AZA alone, TAC alone, or TAC after AZA as
maintenance therapy, after induction therapy with CYC, were
included in this study (Fig. 1). Glucocorticoid pulse therapy (1g
for 3days or 500mg for 5days) was given to all patients for
remission induction therapy, followed by high-dose prednisolone
for at least 4weeks. After the glucocorticoid pulse therapy, 6
cycles of intravenous CYC (15mg/kg, dose adjusted by renal
function and age) was administered. To substantially focus on
TAC and AZA, prednisolone or methylprednisolone was
deliberately not described for convenience in this study. The
present study was performed in accordance with the Declaration
of Helsinki Ethical Principles and was approved by the
Institutional Review Board of Severance Hospital (4-2017-
0673); being a retrospective study, the board waived the need for
written informed consent.
2.3. Medications administered
We reviewed the medical records to gather information regarding
the administration of CYC, RTX, MMF, AZA, MTX, and TAC,
along with prednisolone, in patients with AAV during the follow-
up. Patients prescribed TACwere subdivided into 2 groups: those
taking TAC alone and those prescribed TAC after AZA.
Medications administered were monitored under the Korean
Drug Utilization Review system to prevent omission of any
medications prescribed by other hospitals.
2.4. Data collection
At the time of diagnosis, demographic data were collected, which
included data related to age and sex of the patients. In addition to
AAV subtypes and ANCA positivity, clinical features based on 9
items of the Birmingham vasculitis activity score (BVAS) were
reviewed. As AAV-specific indices, BVAS and five-factor score
(FFS) were assessed. The initial results of the white blood
cell count, hemoglobin, platelet count, creatinine, serum
albumin, aspartate aminotransferase, alanine aminotransferase,
erythrocyte sedimentation rate, and C-reactive protein were
investigated.
2.5. Evaluation of poor outcomes of AAV
Wedefined poor outcomes of AAV as all-causemortality, relapse,
and progression to end-stage renal disease (ESRD) during the
follow-up period. ESRD was defined as a status that requires
renal replacement therapy.
223 patients with AAV 
117 patients with AAV  
who received CYC 
as induction therapy 
Patients with AAV who did not receive CYC as induction therapy (N = 106) 
81 patients with AAV  
who received AZA alone  
or TAC alone or TAC after AZA 
as maintenance therapy 
As maintenance therapy,  
(1) patients with AAV who received MMF alone or MMF after AZA (N = 7) 
(2) patients with AAV who received MTX alone or MTX after AZA (N = 22) 
(3) Patients with AAV who received no AZA, MMF, MTX or TAC (N = 7) 
Figure 1. Selection of the study population. AAV=ANCA-associated vasculitis, AZA=azathioprine, CYC=cyclophosphamide, MMF=mycophenolate mofetil,
TAC= tacrolimus.
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For the surviving patients, the follow-up duration was defined as
the period since initial AAV diagnosis until the last visit. For
deceased patients, the follow-up duration based on all-cause
mortality was defined as the period since initial AAV diagnosis
until death. For patients who presented poor outcomes, the
follow-up duration was defined as the period since initial AAV
diagnosis until each poor outcome appeared.2.7. Statistical analyses
All statistical analyses were conducted using SPSS (version 25 for
Windows; IBM Corp., Armonk, NY). Continuous variables are
expressed asmedianand interquartile range, and categorical variables
are expressed as number and percentage. Significant differences in
categorical variables between groups were analyzed using the x2 and
Fisher exact tests. Significant differences in continuous variables
between groups were compared using the Mann–Whitney test. A
comparison of cumulative survival rates between groups was
performed using Kaplan-Meier survival analysis with the log-rank
test. P values <.05 were considered statistically significant.
3. Results
3.1. Data at diagnosis
The median age was 59.0years, and 50 patients (61.7%) were
women. Among 81 patients, 55 patients were diagnosed with
microscopic polyangiitis, 13 with GPA, and 16 with eosinophilic
granulomatosis with polyangiitis. ANCA was positive in 63
patients. The most common clinical feature was renal manifes-
tations (67.9%), followed by pulmonary manifestations
(54.3%). The median BVAS, FFS, erythrocyte sedimentation
rate, and C-reactive protein were 13.0, 1.0, 63.0mm/h, and 19.1
mg/L, respectively. Themedian values of other routine laboratory
test results are described in Table 1.
3.2. Data during follow-up period
Among 81 patients, 11 patients (13.6%) died of any cause. Thirty
patients (37.0%) experienced relapse, and 16 patients (19.8%)3
required renal replacement therapy. Among 81 patients, AZA
was administered to 75 patients (92.6%) and TAC was
prescribed to 12 patients (14.8%) for maintenance therapy after
induction therapy with CYC. Six patients were prescribed AZA,
with subsequent administration of TAC (Table 1).3.3. Comparison of variables between patients
administered AZA alone and those administered TAC
alone or TAC after AZA
Regarding data at the time of diagnosis, no significant differences
were observed in demographics, AAV subtypes, ANCA positivi-
ty, and clinical features between patients prescribed AZA alone
and those administered TAC alone or TAC after AZA. AAV-
specific indices, routine laboratory results, and acute-phase
reactants did not differ between the groups. In terms of data
during the follow-up period, the period based on all-cause
mortality was longer in patients prescribed TAC alone or TAC
after AZA than in those administered AZA alone (62.8 vs 32.4
months, respectively). Additionally, patients prescribed TAC
alone or TAC after AZA exhibited a higher rate of ESRD
occurrence than those administered AZA alone (41.7% vs
15.9%), but did not demonstrate any significant difference
(Table 1).3.4. Comparison of cumulative survival rates between
patients administered AZA alone and those administered
TAC alone or TAC after AZA
Patients prescribed TAC alone or TAC after AZA exhibited a
lower cumulative ESRD-free survival rate than those prescribed
AZA alone (P= .026). However, no significant differences were
observed in the cumulative patients’ and relapse-free survival
rates between the groups (Fig. 2).
3.5. Comparison of variables among patients who
received AZA alone, TAC alone, and TAC after AZA
First, regarding patients administered AZA alone and TAC alone,
all patients administered TAC alone exhibited pulmonary
Table 1
Demographics of patientswith antineutrophil cytoplasmic antibody-associated vasculitis who received azathioprine alone and thosewho
received tacrolimus alone or after azathioprine.
Variables All patients (N=81) AZA alone (N=69) TAC alone or TAC after AZA (N=12) P
At the time of diagnosis
Demographic data
Age, y 59.0 (23.0) 59.0 (23.0) 61.0 (22.0) .519
Female sex, N (%) 50 (61.7) 43 (62.3) 7 (58.3) 1.000
AAV subtypes (N, (%)) .324
MPA 52 (64.2) 42 (60.9) 10 (83.3)
GPA 13 (16.0) 12 (17.4) 1 (8.3)
EGPA 16 (19.8) 15 (21.7) 1 (8.3)
ANCA positivity, N (%)
MPO-ANCA (or P-ANCA) positive 55 (67.9) 47 (68.1) 8 (66.7) 1.000
PR3-ANCA (or C-ANCA) positive 12 (14.8) 11 (15.9) 1 (8.3) .683
Both ANCA positive 4 (4.9) 4 (5.8) 0 (0) 1.000
ANCA negative 18 (22.2) 15 (21.7) 3 (25.0) .724
Clinical features based on BVAS
General manifestations 39 (48.1) 30 (43.5) 9 (75.0) .061
Cutaneous manifestations 17 (21.0) 16 (23.2) 1 (8.3) .444
Mucous and ocular manifestations 2 (2.5) 1 (1.4) 1 (8.3) .276
Otorhinolaryngologic manifestations 34 (42.0) 29 (42.0) 5 (41.7) 1.000
Pulmonary manifestations 44 (54.3) 35 (50.7) 9 (75.0) .208
Cardiovascular manifestations 19 (23.5) 15 (21.7) 4 (33.3) .462
Gastrointestinal manifestations 5 (6.2) 5 (7.2) 0 (0) 1.000
Renal manifestations 55 (67.9) 46 (66.7) 9 (75.0) .743
Nervous systemic manifestations 32 (39.5) 27 (39.1) 5 (41.7) 1.000
AAV-specific indices
BVAS 13.0 (9.0) 13.0 (8.0) 16.5 (14.8) .531
FFS 1.0 (1.0) 1.0 (1.0) 1.0 (1.0) .890
Comorbidities at diagnosis (n (%))
Chronic kidney disease (stage 3–5) 33 (40.7) 30 (43.5) 3 (25.0) .229
Diabetes mellitus 25 (30.9) 20 (29.0) 5 (41.7) .380
Hypertension 32 (39.5) 25 (78.1) 7 (58.3) .148
Dyslipidemia 18 (22.2) 14 (20.3) 4 (33.3) .316
Routine laboratory results
WBC count (/mm3) 9500.0 (7455.0) 9740.0 (7475.0) 8690.0 (5072.5) .175
Hb, g/dL 10.6 (3.6) 10.9 (3.7) 9.8 (3.6) .186
PLT count (1000/mm3) 292.0 (152.5) 295.0 (153.5) 221.0 (181.5) .128
Creatinine, mg/dL 1.1 (1.6) 1.1 (1.3) 1.3 (5.6) .242
Serum albumin, g/dL 3.6 (1.1) 3.6 (1.2) 3.7 (0.9) .608
Aspartate aminotransferase, IU/L 18.0 (8.5) 18.0 (9.0) 16.0 (3.5) .218
Alanine aminotransferase, IU/L 15.0 (13.0) 15.0 (13.0) 14.0 (7.5) .324
Acute phase reactants
ESR, mm/h 63.0 (81.0) 63.0 (80.5) 51.0 (82.3) .558
CRP, mg/L 19.1 (63.2) 19.1 (59.9) 21.0 (91.0) .489
During the follow-up period
Poor outcomes and follow-up periods
All-cause mortality, N (%) 11 (13.6) 9 (13.0) 2 (16.7) .663
Follow-up period based on all-cause mortality, mo 36.5 (78.3) 32.4 (76.6) 62.8 (123.4) .053
Relapse, N (%) 30 (37.0) 24 (34.8) 6 (50.0) .314
Follow-up period based on relapse, mo 24.7 (39.7) 19.8 (37.9) 26.6 (53.2) .730
ESRD, N (%) 16 (19.8) 11 (15.9) 5 (41.7) .054
Follow-up period based on ESRD, mo 26.2 (55.3) 26.2 (65.3) 26.6 (54.0) .581
Medications administered, N (%)
CYC 81 (100) 69 (100) 12 (100) N/A
AZA 75 (92.6) 69 (100) 6 (50.0) N/A
TAC 12 (14.8) 0 (0) 12 (100) N/A
Values are expressed as a median (interquartile range) or N (%).
AAV=ANCA-associated vasculitis, ANCA=antineutrophil cytoplasmic antibody, AZA= azathioprine, BVAS=Birmingham vasculitis activity score, C= cytoplasmic, CRP=C-reactive protein, CYC=
cyclophosphamide, EGPA= eosinophilic granulomatosis with polyangiitis, ESR= erythrocyte sedimentation rate, ESRD= end-stage renal disease, FFS=five-factor score, GPA=granulomatosis with polyangiitis,
Hb=haemoglobin, MPA=microscopic polyangiitis, MPO=myeloperoxidase, N/A=not applicable, P=perinuclear, PLT=platelet, PR3=proteinase 3, TAC= tacrolimus, WBC=white blood cell.
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Figure 2. Kaplan-Meier curves comparing patients who received AZA alone
and TAC alone or TAC after AZA. There were no differences in the cumulative
patients’ and relapse-free survival rates between patients prescribed TAC
alone or TAC after AZA. Patients prescribed TAC alone or TAC after AZA
exhibited a lower cumulative ESRD-free survival rate than those prescribed
AZA alone (P= .026). AZA=azathioprine, ESRD=end-stage renal disease,
TAC= tacrolimus.
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tered AZA alone exhibited these manifestations (P= .029). Other
variables did not differ between these groups. Second, regarding
patients administered AZA alone and administered TAC after
AZA, patients administered TAC after AZA hadmore underlying
hypertension than those administered AZA alone (P= .035).
Third, regrading patients administered TAC alone and adminis-
tered TAC after AZA, FFS at diagnosis was significantly higher in
patients administered TAC alone than in those administered TAC
after AZA (P= .044). However, its statistical significance was too5
low to propose clinical implications. The incidence rates of poor
AAV outcomes did not differ among the 3 groups (Table 2).3.6. Comparison of cumulative survival rates among
patients administered AZA alone, TAC alone, and TAC
after AZA
Between patients who received AZA alone and TAC alone, no
significant differences were observed in the cumulative patients’,
relapse-free, and ESRD-free survival rates. Meanwhile, patients
who received TAC after AZA exhibited a lower cumulative
ESRD-free survival rate than those who received AZA alone
(P= .027). Other cumulative survival rates did not differ between
patients who received AZA alone and those who received TAC
after AZA. The cumulative patients’, relapse-free, and ESRD-free
survival rates did not differ between patients who received TAC
alone and those who received TAC after AZA (Fig. 3).
4. Discussion
Our study is the first to investigate the therapeutic potential of
TAC as maintenance therapy for AAV treatment in a consider-
able number of patients, to the best of our knowledge. In the
present study, we demonstrated that patients who received TAC
for maintenance therapy showed comparable outcomes for
survival and relapse with those who received AZA for
maintenance therapy. However, the risk for ESRD occurrence
was higher in patients who received TAC than those who received
AZA.
In this study, themost significant difference was observed in the
incidence rates of ESRD in patients who received TAC and those
who received AZA alone during the follow-up period. More
precisely, patients administered TAC after AZA as maintenance
therapy showed a high incidence rate of ESRD. What factors
influenced these outcomes?
First, we questioned whether glomerulonephritis was more
severe or renal function had decreased more at the time of
diagnosis in patients administered TAC after AZA than in those
who received AZA alone. As a result, baseline serum creatinine
level was higher in patients administered TAC after AZA than in
those administered AZA alone (2.8 vs 1.1mg/dL). Furthermore,
we pondered whether there were any factors other than kidney-
related variables that present a distinct difference at the time of
diagnosis between patients who received TAC after AZA and
those administered AZA alone. A greater proportion of patients
who received TAC after AZA had underlying hypertension than
those who received AZA alone (83.3% vs. 36.2%) (Table 2).
These factors may have resulted in high incidence of ESRD in
patients administered TAC after AZA.
We focused on the reasons for switching from AZA to TAC.
Among six patients administered TAC after AZA, five patients
switched from AZA to TAC due to lack of efficacy and one
patient owing to elevated levels of hepatic enzymes.[19] Among 5
patients who switched medications due to a lack of efficacy, 4
suffered from decreased renal function, three of whomprogressed
to ESRD. In other words, before drug switching, a sudden decline
in kidney function had commenced. However, there was little
need for drug switching in patients who maintained AZA, as no
sudden decline in kidney function was observed. Therefore, it can
be concluded that the decline in renal function while receiving
AZA was the key reason for progression to ESRD, rather than
that TAC was less effective in maintaining renal functions than
Table 2
Comparison of variables among patients with antineutrophil cytoplasmic antibody-associated vasculitis who were administered
azathioprine alone, tacrolimus alone, and tacrolimus after azathioprine.
Variables AZA alone [1] (N=69) TAC alone [2] (N=6) TAC after AZA [3] (N=6) P (1 vs 2) P (1 vs 3) P (2 vs 3)
At the time of diagnosis
Demographic data
Age, y) 59.0 (23.0) 64.0 (16.8) 58.5 (31.8) .333 .984 .520
Female sex, N (%) 43 (62.3) 4 (66.7) 3 (50.0) 1.000 .671 1.000
AAV subtypes, N (%) .417 .460 .368
MPA 42 (60.9) 5 (83.3) 5 (83.3)
GPA 12 (17.4) 1 (16.7) 0 (0)
EGPA 15 (21.7) 0 (0) 1 (16.7)
ANCA positivity, N (%)
MPO-ANCA (or P-ANCA) positive 47 (68.1) 4 (66.7) 4 (66.7) 1.000 1.000 1.000
PR3-ANCA (or C-ANCA) positive 11 (15.9) 1 (16.7) 0 (0) 1.000 .583 1.000
Both ANCA positive 4 (5.8) 0 (0) 0 (0) 1.000 1.000 N/A
ANCA negative 15 (21.7) 1 (16.7) 2 (33.3) 1.000 .613 1.000
Clinical features based on BVAS
General manifestations 30 (43.5) 5 (83.3) 4 (66.7) .092 .401 1.000
Cutaneous manifestations 16 (23.2) 0 (0) 1 (16.7) .331 1.000 1.000
Mucous and ocular manifestations 1 (1.4) 1 (16.7) 0 (0) .155 1.000 1.000
Otorhinolaryngologic manifestations 29 (42.0) 1 (16.7) 4 (66.7) .392 .395 .242
Pulmonary manifestations 35 (50.7) 6 (100) 3 (50.0) .029 1.000 .182
Cardiovascular manifestations 15 (21.7) 3 (50.0) 1 (16.7) .145 1.000 .545
Gastrointestinal manifestations 5 (7.2) 0 (0) 0 (0) 1.000 1.000 N/A
Renal manifestations 46 (66.7) 5 (83.3) 4 (66.7) .657 1.000 1.000
Nervous systemic manifestations 27 (39.1) 2 (33.3) 3 (50.0) 1.000 .678 1.000
AAV-specific indices
BVAS 13.0 (8.0) 17.0 (17.5) 16.5 (12.3) .604 .688 .688
FFS 1.0 (1.0) 2.0 (2.0) 1.0 (1.3) .149 .214 .044
Comorbidities at diagnosis, n (%)
Chronic kidney disease (stage 3–5) 30 (43.5) 2 (33.3) 1 (16.7) .630 .391 1.000
Diabetes mellitus 20 (29.0) 3 (50.0) 2 (33.3) .284 1.000 1.000
Hypertension 25 (36.2) 2 (33.3) 5 (83.3) .887 .035 0.242
Dyslipidemia 14 (20.3) 2 (33.3) 2 (12.5) .602 .602 1.000
Routine laboratory results
WBC count (/mm3) 9740.0 (7475.0) 8690.0 (6375.0) 9190.0 (7112.5) .319 .319 1.000
Hb, g/dL 10.9 (3.7) 10.0 (2.0) 8.7 (5.2) .429 .249 .335
PLT count (1000/mm3) 295.0 (153.5) 221.0 (174.8) 230.5 (201.5) .257 .270 .749
Creatinine, mg/dL 1.1 (1.3) 1.2 (6.7) 2.8 (5.8) .435 .348 .936
Serum albumin, g/dL 3.6 (1.2) 3.7 (1.3) 3.7 (0.8) .519 .914 .748
Aspartate aminotransferase, IU/L 18.0 (9.0) 16.0 (6.5) 16.0 (12.5) .544 .229 .618
Alanine aminotransferase, IU/L 15.0 (13.0) 14.0 (16.8) 12.0 (17.8) .822 .222 .333
Acute phase reactants
ESR, mm/h 63.0 (80.5) 34.0 (83.5) 76.0 (63.3) .252 .777 .297
CRP, mg/L 19.1 (59.9) 10.5 (48.3) 70.0 (112.1) .799 .204 .336
During the follow-up period
Poor outcomes and follow-up periods
All-cause mortality, N (%) 9 (13.0) 0 (0) 2 (33.3) 1.000 .211 .455
Follow-up period based on all-cause mortality, mo 32.4 (76.6) 53.8 (140.7) 68.6 (111.2) .125 .191 .873
Relapse, N (%) 24 (34.8) 2 (33.3) 4 (66.7) 1.000 .188 .567
Follow-up period based on relapse, mo 19.8 (37.9) 26.6 (71.7) 31.5 (99.0) .961 .646 .631
ESRD, N (%) 11 (15.9) 2 (33.3) 3 (50.0) .277 .075 1.000
Follow-up period based on ESRD, mo 26.2 (65.3) 23.8 (62.6) 36.3 (57.4) .500 .891 .378
Values are expressed as a median (interquartile range) or N (%).
AAV=ANCA-associated vasculitis, ANCA= antineutrophil cytoplasmic antibody, AZA= azathioprine, BVAS=Birmingham vasculitis activity score, C= cytoplasmic, CRP=C-reactive protein, EGPA= eosinophilic
granulomatosis with polyangiitis, ESR=erythrocyte sedimentation rate, ESRD= end-stage renal disease, FFS= five-factor score, GPA=granulomatosis with polyangiitis, Hb=haemoglobin, MPA=microscopic
polyangiitis, MPO=myeloperoxidase, N/A=not applicable, P=perinuclear, PLT=platelet, PR3=proteinase 3, TAC= tacrolimus, WBC=white blood cell.
Pyo et al. Medicine (2021) 100:34 MedicineAZA.We believe that only 2 of 6 patients who received TAC only
as maintenance therapy progressed to ESRD, which supports our
hypothesis.
Follow-up period based on all-cause mortality was longer in
patients administered TAC alone or TAC after AZA than those
administered AZA alone. Nine patients died among patients6
administered AZA alone, whereas those administered TAC alone
had no mortality. Two cases of mortality among patients treated
with TAC was among those treated with TAC after AZA, not
TAC alone. This might be the factor affecting the difference in
follow-up period, because patients who switched taking AZA to
TAC inevitably have a longer follow-up duration because they
Figure 3. Kaplan-Meier curves comparing patients who received AZA alone, TAC alone, and TAC after AZA. No differences were observed in the cumulative
patients’, relapse-free, and ESRD-free survival rates between patients who received AZA alone and TAC alone or between patients who received TAC alone and
those who received TAC after AZA. Patients who received TAC after AZA showed a lower cumulative ESRD-free survival rate than those who received AZA alone
(P=0.027), but cumulative patients’, and relapse-free survival rates did not differ between the groups. AZA=azathioprine, ESRD=end-stage renal disease, TAC=
tacrolimus.
Pyo et al. Medicine (2021) 100:34 www.md-journal.cominclude the period of taking AZA. Although the number of
patients was small, despite the follow-up period was numerically
longer in patients treated with TAC alone than those treated with
AZA alone there were no deaths in the patients treated with TAC
alone, indicating the efficacy of TAC.
For maintenance therapy, drugs that have demonstrated
efficacy through randomized controlled trials include AZA,
MTX, and RTX.[20] Among these, MTX is recommended as
maintenance therapy in patients with relatively nonsevere AAV.
In a study demonstrating the effectiveness of MMF and AZA as
maintenance therapy after induction therapy, the relapse rate in
patients who received MMF was higher than that in those who
received AZA.[21] Based on these findings, AZA has been the
most widely used drug for maintenance therapy in the current
general clinical settings.[4]
Nevertheless, in this study, TAC was selected as maintenance
therapy for the following reasons. With respect to patients who
received TAC after AZA, all 6 patients who demonstrated a lack
of AZA efficacy strongly opposed the re-administration of CYC,7
as well as RTX administration, owing to concerns regarding
adverse drug reactions. MMF was excluded from consideration
as the risk of recurrence with MMF was higher than that with
AZA.[21]
In contrast, with TAC as the first maintenance therapeutic
regimen, all six patients demonstrated reasons for difficulties with
AZA—2 patients presented elevated liver enzyme levels and four
patients presented leukocytopenia.[19,22] The rate of kidney
involvement was high (83.3%) in these 6 patients; however, RTX
did not meet the criteria for health insurance coverage and the
effectiveness of MTX as maintenance therapy for treating
patients with AAV and kidney involvement was not con-
firmed.[23] TAC seemed to have significantly prevented ESRD,
considering that only 2 of 5 patients with kidney involvement
who were prescribed TAC as the first maintenance therapy
developed ESRD.
Presently, TAC has proven efficacy in lupus nephritis and is
actively recommended for treating lupus nephritis as a
combination therapy with prednisolone or prednisolone plus
Pyo et al. Medicine (2021) 100:34 MedicineMMF based on randomized controlled trials.[24–26] Although
lupus nephritis is characterized by the deposition of immune
complexes, demonstrating considerably different pathological
findings from AAV, the therapeutic effect of TAC could be
significant as TH1, TH17, and effector T cells are actively involved
in the pathogenesis of both diseases.[16,27] Notably, this study
provided evidence that the efficacy of TAC is comparable to that
of AZA as an alternative therapeutic option in patients with
AAV. Therefore, a prospective clinical study to investigate the
efficacy of TAC for treating AAV, particularly AAV with renal
involvement, is warranted.
To the best of our knowledge, our report is the first pilot study
investigating the therapeutic potential of TAC as maintenance
therapy for AAV treatment in a considerable number of patients.
However, our studyhas several limitations owing to its retrospective
design and the small number of patients who received TAC. The
most significant limitation is that thediseasestatus at the timeofdrug
switching may differ between the groups. Additionally, there may
have been a selection bias because our study is a retrospective single-
center study, and thenumber of patientswas insufficient to verify the
statistical significance. Furthermore, cumulative dose of glucocorti-
coidsmay differ between patients who received TACand thosewho
received AZA because disease status such as disease duration,
inflammatory burden, and relapsed or not may differ for each
patient. For these reasons, our results should be interpreted with
caution, and well-designed prospective studies are needed. Never-
theless, our study has clinical implication in investigating the
potential efficacy of TAC as amaintenance therapy for AAV,which
has only limited drug options. Future prospective studies with a
larger patient population could overcome these limitations and
validate our results.Webelieve that our studywillmake a significant
contribution to patients with AAV in clinical settings and anticipate
that our study will serve as an opportunity to initiate clinical studies
demonstrating the therapeutic effect of TAC in the treatment of
AAV.5. Conclusions
Patientswho receivedTACasmaintenance therapy showedahigher
incidence of ESRD than those who received AZA, but this might be
attributed to the lack of efficacy of AZA rather than the low ESRD
prevention effect of TAC as maintenance therapy after CYC.Author contributions
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